Immunotherapy for renal carcinoma: theoretical basis and current standard of care.
作者信息
Vasey P A
机构信息
CRC Department of Medical Oncology, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD.
出版信息
Br J Clin Pharmacol. 2000 Dec;50(6):521-9. doi: 10.1046/j.1365-2125.2000.00300.x.
Abstract
摘要
相似文献
1
Immunotherapy for renal carcinoma: theoretical basis and current standard of care.肾癌的免疫疗法：理论基础与当前护理标准。
Br J Clin Pharmacol. 2000 Dec;50(6):521-9. doi: 10.1046/j.1365-2125.2000.00300.x.
2
Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.2006年及以后细胞因子疗法在转移性肾细胞癌治疗中的作用
J Clin Oncol. 2006 Dec 10;24(35):5584-92. doi: 10.1200/JCO.2006.08.1638.
3
The role of adoptive immunotherapy in solid cancers.过继性免疫疗法在实体癌中的作用。
Neth J Med. 1997 Feb;50(2):47-68. doi: 10.1016/s0300-2977(96)00083-6.
4
Immunotherapy for renal cell carcinoma.肾细胞癌的免疫治疗。
Hematol Oncol Clin North Am. 2011 Aug;25(4):793-812. doi: 10.1016/j.hoc.2011.04.010.
5
Renal cancer immunotherapy: a ray of hope or regression to the mean?肾癌免疫疗法：一线希望还是回归均值？
Cancer Invest. 2000;18(5):490-1. doi: 10.3109/07357900009032820.
6
Renal cell cancer: is immunotherapy dead?肾细胞癌：免疫疗法是否已无前景？
Ann Oncol. 2007 Jul;18 Suppl 9:ix94-7. doi: 10.1093/annonc/mdm302.
7
Immunotherapy for metastatic renal cell carcinoma.转移性肾细胞癌的免疫疗法。
BJU Int. 2007 May;99(5 Pt B):1282-8. doi: 10.1111/j.1464-410X.2007.06818.x.
8
[The role of immunotherapy in metastatic cancer of the kidney].[免疫疗法在肾转移性癌中的作用]
J Urol (Paris). 1994;100(5):231-7.
9
Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.转移性肾细胞癌诱导和维持免疫治疗的当前临床实践。
Int J Clin Pract. 2002 Jan-Feb;56(1):36-9.
10
[Immunotherapy for advanced renal cell cancer].[晚期肾细胞癌的免疫疗法]
Urologe A. 2015 May;54(5):716-20. doi: 10.1007/s00120-015-3825-0.
本文引用的文献
1
Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.干扰素α-2a联合长春碱与单纯长春碱治疗晚期肾细胞癌的前瞻性随机试验
J Clin Oncol. 1999 Sep;17(9):2859-67. doi: 10.1200/JCO.1999.17.9.2859.
2
Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma.
Clin Cancer Res. 1999 Sep;5(9):2374-80.
3
4
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.重组人白细胞介素-2、重组人干扰素α-2a或两者联合用于转移性肾细胞癌。法国免疫治疗小组。
N Engl J Med. 1998 Apr 30;338(18):1272-8. doi: 10.1056/NEJM199804303381805.
5
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.与安慰剂相比，干扰素γ-1b治疗转移性肾细胞癌的疗效。加拿大泌尿外科肿瘤学组。
N Engl J Med. 1998 Apr 30;338(18):1265-71. doi: 10.1056/NEJM199804303381804.
6
The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy.
Cancer J Sci Am. 1997 Dec;3 Suppl 1:S109-14.
7
Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience.吸入性白细胞介素-2治疗肺转移性肾细胞癌：六年经验
Cancer J Sci Am. 1997 Dec;3 Suppl 1:S98-105.
8
Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2.转移性肾细胞癌：大剂量持续输注白细胞介素-2治疗后的长期生存情况
Cancer J Sci Am. 1997 Dec;3 Suppl 1:S85-91.
9
An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.白细胞介素-2治疗转移性肾细胞癌方案的前瞻性随机对照研究。
Cancer J Sci Am. 1997 Dec;3 Suppl 1:S79-84.
10
Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.基于白细胞介素-2的转移性肾细胞癌治疗：细胞因子工作组的经验，1989 - 1997年
Cancer J Sci Am. 1997 Dec;3 Suppl 1:S73-8.
Zotero 插件